FDA Brief

Warning letters Drugs

FDA warning letter to

Patcos Cosmetics Pvt. Ltd.

High riskIssued Mar 12Posted Mar 17Center for Drug Evaluation and Research (CDER)

Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.

What happened

FDA conducted an unannounced inspection of Patcos Cosmetics' drug manufacturing facility in Daman, India, from July 14 to 18, 2025. Investigators observed insanitary conditions, including harborage areas, a broken window, water damage, mold-like residue, and production-area sinks used as a water source for cleaning equipment. FDA also cited CGMP violations for inadequate identity testing of high-risk components, poor system and process validation, quality-unit failures, and data integrity problems, and it found the company's August 11, 2025, response inadequate.

What FDA found

  1. Drug products were prepared, packed, or held under insanitary conditions that could contaminate them with filth or make them injurious to health.

    FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)
  2. The firm failed to keep buildings used for drug manufacturing in a good state of repair, with dirt, water damage, and mold-like residue in production and storage areas.

    21 CFR 211.58
  3. The firm failed to conduct at least one identity test for each incoming component lot, including high-risk components, and its third-party test methods were not validated or verified.

    21 CFR 211.84(d)(1)
  4. The firm failed to establish adequate written production and process controls, including adequate validation and monitoring of a manufacturing system and validation of manufacturing processes, and some batches were super potent.

    21 CFR 211.100(a)
  5. The quality unit failed to oversee laboratory data, batch records, specifications, and stability testing, including failing to prevent alteration of original data to conceal out-of-specification results.

    21 CFR 211.22(a) and (d)
  6. The firm lacked adequate data integrity controls, including deliberate alteration of original laboratory data.

    21 CFR 211.194

What FDA wants

FDA tells Patcos to provide comprehensive facility, system, process-validation, quality-unit, and data-integrity remediation plans, plus risk assessments and customer notifications or recalls for affected lots. It also asks for high-risk component test results within 30 calendar days.

Who should pay attention

  • brands and distributors that buy OTC drugs from this contract manufacturer
  • companies sourcing ingredients or finished products from Indian drug manufacturers
  • quality teams managing supplier qualification and data integrity

This is a summary. Read the original letter on fda.gov.

Patcos Cosmetics Pvt. Ltd.'s FDA history

  1. Patcos Cosmetics Pvt. Ltd.

    CGMP/Finished Pharmaceuticals/Adulterated

Full company page

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. ABC Food Corp

    ABC Food Corp's ready-to-eat rice noodles and tofu were made without required hazard analysis and preventive controls.

    High risk
  3. Rama Food Manufacture Corp.

    FDA warns Rama Food Manufacture after inspections found insanitary conditions and preventive-control failures at its California ready-to-eat rice noodle plants.

    High risk
  4. Lewis Sausage Company Inc.

    FDA found Salmonella and Listeria in contract-made pet food from Lewis Sausage and says its pathogen controls are inadequate.

    High risk